Probiotic-Assisted Therapy for H. pylori: Clinical Insights from Weizmannia coagulans BC99（ChiCTR2300073499）

The Challenge of H. pylori and the Promise of Probiotics

H. pylori is a common prevalent gastric pathogen that can lead to serious issues like ulcers and even gastric cancer. While traditional bismuth quadruple therapy (BQT) works well, it has limitations, including antibiotic resistance and side effects. That’s where Weizmannia coagulans BC99 comes in—offering a promising probiotic boost to treatment, supporting both eradication and gut health.

In this placebo-controlled clinical study, we evaluated whether BC99 can enhance H. pylori eradication, alleviate upper-GI symptoms, and help maintain gut microbiota balance. 100 H. pylori-positive participants were assigned to BC99 or placebo for six weeks alongside standard BQT. The results were encouraging.

Key Insights:

1. Enhanced H. pylori Eradication: The BC99 group showed a significantly higher H. pylori eradication rate (95.35%) compared to the placebo group (81.57%), indicating that BC99 boosts the effectiveness of traditional BQT therapy.

2. Improved Gastrointestinal Symptoms: Patients in the BC99 group experienced significant improvements in gastrointestinal symptoms, particularly stomach pain during hunger and acid reflux, as measured by the GSRS.

3. Better Gastric Function and Lower Inflammation: BC99 was associated with improvements in gastric function, reflected by higher serum pepsinogen I levels, and with reductions in study-assessed inflammatory measures.

4. Restoration of Gut Microbiota: BBC99 helped rebalance the gut microbiota, increasing beneficial genera such as Prevotella, Bacillus, and Candidatus Saccharimonas, a profile commonly linked with stronger mucosal resilience and improved digestive comfort during therapy.

5. Fewer Adverse Events: The incidence of adverse events was lower in the BC99 group, particularly in terms of nausea and drug fever, suggesting BC99’s potential to reduce side effects during treatment.

Weizmannia coagulans BC99 supplementation is an effective adjunct therapy improves eradication rates of H. pylori treatment. It significantly alleviates gastrointestinal symptoms, and supports gut health by balancing the microbiota and reducing inflammation. This study highlights the potential of targeted probiotics to enhance both the safety and efficacy of conventional H. pylori eradication treatment.

References:

Wu, Y., Zhai, S., Wang, C., et al. (2025). Weizmannia coagulans BC99 modulates gut microbiota after Helicobacter pylori eradication: A randomized double-blind placebo-controlled trial. Journal of Functional Foods. DOI: 10.1016/j.jff.2025.106681